HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badzio, A. Articles by Jassem, J. Search for Related Content PubMed PubMed Citation Articles by Badzio, A. Articles by Jassem, J. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2004;26:183-188
© 2004 Elsevier Science NL

A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer

^a Department of Oncology and Radiotherapy, Medical University of Gdask, ul. Debinki 7, 80-211 Gdask, Poland
^b Department of Thoracic Surgery, Medical University of Gdask, Gdask, Poland
^c Department of Chemotherapy, PCK Maritime Hospital, Gdynia, Poland

Received 7 January 2004; received in revised form 8 April 2004; accepted 13 April 2004.

^* Corresponding author. Tel./fax: +45-58-3492270
e-mail: jjassem{at}amg.gda.pl

Objective: The role of surgery in limited SCLC is still a matter of controversy. Even though the response rates to chemotherapy are very high, prognosis of SCLC patients has remained poor with a median survival of only 12–14 months for limited disease. High incidence of local relapses after chemotherapy in limited-stage SCLC led to reassessment of the role of local treatment in the multimodality management of this tumor. Methods: We performed retrospective comparative analysis of survival in a series of 134 limited-stage SCLC patients treated between 1984 and 1996 with either complete resection followed by chemotherapy (67 patients), or with conventional non-surgical management (67 patients). In all patients who underwent resection, the diagnosis of SCLC was established only postoperatively. The control (non-surgical) group was selected using ‘pair-matched case-control’ methodology, out of 176 limited-stage patients potentially suitable for surgery (i.e. with no pleural effusion or other local advancement, no supraclavicular lymph node involvement and good performance status), but treated without resection. The major prognostic factors were well balanced between these two groups. Total series included 109 males and 25 females, 20 patients with T1 and 114 patients with T2 disease, 51 N0, 43 N1 and 40 N2 disease. Results: Median survival in patients treated with and without surgery was 22 months and 11 months, respectively, (P<0.001). The two-year and five-year survival probabilities were 43 and 27%, respectively, in the surgical group, and 17 and 4%, respectively, in the non-surgical group. Subset analysis confirmed significantly longer survival with surgery in all T and N categories, except for N2 disease. Local relapse occurred in 15 and 55% of patients treated with and without surgery, respectively, (P<0.001). Distant relapse probabilities were similar in both groups (36 and 40%, respectively). The most common site of metastases in the entire series was brain, followed by liver, lymph nodes, bone, lung and skin. Conclusions: Our results suggest a possible role of surgery in limited-stage SCLC. Thus, a randomised study addressing this issue seems to be justified.

Key Words: Small cell lung cancer • Limited disease • Surgery • Local control • Comparative study

This article has been cited by other articles:

				M. A. Socinski and J. A. Bogart Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145. [Abstract] [Full Text] [PDF]

				D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]

				A. Granetzny, A. Boseila, W. Wagner, G. Krukemeyer, U. Vogt, E. Hecker, O. M. Koch, and F. Klinke Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 212 - 216. [Abstract] [Full Text] [PDF]

				M. V. Brock, C. M. Hooker, J. E. Syphard, W. Westra, L. Xu, A. J. Alberg, D. Mason, S. B. Baylin, J. G. Herman, R. C. Yung, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 64 - 72. [Abstract] [Full Text] [PDF]